Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(33%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting2
Recruiting2
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

terminated117%
not_yet_recruiting233%
recruiting233%
completed117%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_2

A Phase II Study of GC101 in NSCLC

NCT07560111
recruitingphase_1

A Phase Ib Study of GC101 in NSCLC

NCT06473961
completedphase_1

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

NCT04812470
recruitingphase_1

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

NCT06084299
terminatedphase_1

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07560111Phase 2

A Phase II Study of GC101 in NSCLC

Not Yet Recruiting
NCT06473961Phase 1

A Phase Ib Study of GC101 in NSCLC

Recruiting
NCT04812470Phase 1

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Completed
NCT06084299Phase 1

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Recruiting
NCT03991741Phase 1

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Terminated
NCT05903937Phase 1

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6